Metformin Use is Associated with Low Risk of Case Fatality and Disability Rates in First-ever Stroke Patients with Type 2 Diabetes

Overview

Journal Ther Adv Chronic Dis

Publisher Sage Publications

Date 2022 Apr 25

PMID 35465053

Authors

Wen-Jun Tu

Zheng Liu

Bao-Hua Chao

Feng Yan

Lin Ma

Lei Cao

Xun-Ming Ji

Long-de Wang

Affiliations

Soon will be listed here.

Abstract

Background: To assess the effectiveness of metformin treatment on long-term outcomes in first-ever stroke patients with type 2 diabetes mellitus (T2DM) in China.

Methods: From August to September 2019, all patients with first-ever stroke and T2DM from 232 hospitals in China Mainland were included. The enrolled patients were divided into two groups: the metformin treatment (MT) and the no-metformin treatment (No-MT) groups. All discharged patients would receive a telephone follow-up at 12-month after admission.

Results: In total, 7587 first-ever stroke patients with T2DM [age: median (IQR) = 66 (57-73) years; 57.35% male] were recruited. Out of those 7587 included patients, 3593 (47.36%) received MT. The in-hospital case fatality rate was lower in the MT group than the No-MT group [MT group No-MT group: 1.09% 2.30%; absolute difference = -1.75% (95% CI = -2.15 to -1.17%); OR = 0.63 (95% CI = 0.47 to 0.84)]. The 12-month case fatality rate was lower in the MT group than the No-MT group [4.72% 8.05%; absolute difference = -4.05% (95% CI = -5.58 to -2.41); OR = 0.69 (95% CI = 0.50 to 0.88)]. The 12-month disability rate was also lower in the MT group than the No-MT group [14.74% 19.41%; absolute difference = -5.70% (95% CI = -7.25 to -3.22); OR = 0.83 (95% CI = 0.70 to 0.95)]. Furthermore, the recurrence rate did not differ significantly between the MT and No-MT groups ( = 0.29).

Conclusion: The study reveals that metformin use in stroke patients with T2DM results in a less severe stroke and lower fatality and disability rates.

Citing Articles

Metformin's Effects on Cognitive Function from a Biovariance Perspective: A Narrative Review.

Chele D, Sirbu C, Mitrica M, Toma M, Vasiliu O, Sirbu A Int J Mol Sci. 2025; 26(4).

PMID: 40004246 PMC: 11855408. DOI: 10.3390/ijms26041783.

Impact of Prior Metformin Use on Stroke Outcomes: A Systematic Review and Updated Meta-Analysis.

Elgenidy A, Shaban A, Saad K, Hamed Y, Rhab A, Darwish M J Clin Med Res. 2025; 17(2):76-88.

PMID: 39981342 PMC: 11835556. DOI: 10.14740/jocmr6159.

Effect of metformin on the clinical outcomes of stroke in patients with diabetes: a systematic review and meta-analysis.

Liu J, Huang Z, Luo F, Guo Y, Li Y, Wen J BMJ Open. 2025; 15(1):e092214.

PMID: 39819905 PMC: 11751969. DOI: 10.1136/bmjopen-2024-092214.

Impaired glucose metabolism and the risk of vascular events and mortality after ischemic stroke: A systematic review and meta-analysis.

Kaynak N, Kennel V, Rackoll T, Schulze D, Endres M, Nave A Cardiovasc Diabetol. 2024; 23(1):323.

PMID: 39217364 PMC: 11366144. DOI: 10.1186/s12933-024-02413-w.

Effectiveness of metformin pretreatment for stroke severity: A propensity score matching study.

Zhang B, Silverman S, Schwammn L, Ji X, Singhal A CNS Neurosci Ther. 2024; 30(8):e70004.

PMID: 39169599 PMC: 11339120. DOI: 10.1111/cns.70004.

References

Torres W, Nava M, Galban N, Gomez Y, Morillo V, Rojas M . Anti-Aging Effect of Metformin: A Molecular and Therapeutical Perspective. Curr Pharm Des. 2020; 26(35):4496-4508. DOI: 10.2174/1381612826666200716161610. View

Benjanuwattra J, Apaijai N, Chunchai T, Kerdphoo S, Jaiwongkam T, Arunsak B . Metformin preferentially provides neuroprotection following cardiac ischemia/reperfusion in non-diabetic rats. Biochim Biophys Acta Mol Basis Dis. 2020; 1866(10):165893. DOI: 10.1016/j.bbadis.2020.165893. View

Ashabi G, Khalaj L, Khodagholi F, Goudarzvand M, Sarkaki A . Pre-treatment with metformin activates Nrf2 antioxidant pathways and inhibits inflammatory responses through induction of AMPK after transient global cerebral ischemia. Metab Brain Dis. 2014; 30(3):747-54. DOI: 10.1007/s11011-014-9632-2. View

Bromage D, Godec T, Pujades-Rodriguez M, Gonzalez-Izquierdo A, Denaxas S, Hemingway H . Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes: a cohort study. Cardiovasc Diabetol. 2019; 18(1):168. PMC: 6900858. DOI: 10.1186/s12933-019-0972-4. View

Petrie J, Rossing P, Campbell I . Metformin and cardiorenal outcomes in diabetes: A reappraisal. Diabetes Obes Metab. 2020; 22(6):904-915. PMC: 7317924. DOI: 10.1111/dom.13984. View

Li Y, Teng D, Shi X, Qin G, Qin Y, Quan H . Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ. 2020; 369:m997. PMC: 7186854. DOI: 10.1136/bmj.m997. View

Castilla-Guerra L, Fernandez-Moreno M, Leon-Jimenez D, Carmona-Nimo E . Antidiabetic drugs and stroke risk. Current evidence. Eur J Intern Med. 2017; 48:1-5. DOI: 10.1016/j.ejim.2017.09.019. View

Evans J, Donnelly L, Emslie-Smith A, Alessi D, Morris A . Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005; 330(7503):1304-5. PMC: 558205. DOI: 10.1136/bmj.38415.708634.F7. View

Bjorkhem-Bergman L, Asplund A, Lindh J . Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis. J Psychopharmacol. 2010; 25(3):299-305. DOI: 10.1177/0269881109353461. View

10.

Tseng C . Metformin Use Is Associated With a Lower Risk of Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus: a Retrospective Cohort Analysis. J Am Heart Assoc. 2019; 8(21):e011640. PMC: 6898844. DOI: 10.1161/JAHA.118.011640. View

11.

Venna V, Li J, Hammond M, Mancini N, McCullough L . Chronic metformin treatment improves post-stroke angiogenesis and recovery after experimental stroke. Eur J Neurosci. 2014; 39(12):2129-38. PMC: 4061245. DOI: 10.1111/ejn.12556. View

12.

Roumie C, Chipman J, Min J, Hackstadt A, Hung A, Greevy Jr R . Association of Treatment With Metformin vs Sulfonylurea With Major Adverse Cardiovascular Events Among Patients With Diabetes and Reduced Kidney Function. JAMA. 2019; 322(12):1167-1177. PMC: 6753652. DOI: 10.1001/jama.2019.13206. View

13.

Cheng Y, Leu H, Chen T, Chen C, Kuo C, Lee S . Metformin-inclusive therapy reduces the risk of stroke in patients with diabetes: a 4-year follow-up study. J Stroke Cerebrovasc Dis. 2013; 23(2):e99-105. DOI: 10.1016/j.jstrokecerebrovasdis.2013.09.001. View

14.

Tu W, Chao B, Ma L, Yan F, Cao L, Qiu H . Case-fatality, disability and recurrence rates after first-ever stroke: A study from bigdata observatory platform for stroke of China. Brain Res Bull. 2021; 175:130-135. DOI: 10.1016/j.brainresbull.2021.07.020. View

15.

Jin Q, Cheng J, Liu Y, Wu J, Wang X, Wei S . Improvement of functional recovery by chronic metformin treatment is associated with enhanced alternative activation of microglia/macrophages and increased angiogenesis and neurogenesis following experimental stroke. Brain Behav Immun. 2014; 40:131-42. DOI: 10.1016/j.bbi.2014.03.003. View

16.

Zhou C, Sun R, Zhuang S, Sun C, Jiang Y, Cui Y . Metformin prevents cerebellar granule neurons against glutamate-induced neurotoxicity. Brain Res Bull. 2016; 121:241-5. DOI: 10.1016/j.brainresbull.2016.02.009. View

17.

Mudgal J, Nampoothiri M, Mallik S, Kinra M, Hall S, Grant G . Possible involvement of metformin in downregulation of neuroinflammation and associated behavioural changes in mice. Inflammopharmacology. 2019; 27(5):941-948. DOI: 10.1007/s10787-019-00638-w. View

18.

Mima Y, Kuwashiro T, Yasaka M, Tsurusaki Y, Nakamura A, Wakugawa Y . Impact of Metformin on the Severity and Outcomes of Acute Ischemic Stroke in Patients with Type 2 Diabetes Mellitus. J Stroke Cerebrovasc Dis. 2016; 25(2):436-46. DOI: 10.1016/j.jstrokecerebrovasdis.2015.10.016. View

19.

Leech T, Apaijai N, Palee S, Higgins L, Maneechote C, Chattipakorn N . Acute administration of metformin prior to cardiac ischemia/reperfusion injury protects brain injury. Eur J Pharmacol. 2020; 885:173418. DOI: 10.1016/j.ejphar.2020.173418. View

20.

Dy A, Tassone F, Eldeeb M, Salcedo-Arellano M, Tartaglia N, Hagerman R . Metformin as targeted treatment in fragile X syndrome. Clin Genet. 2017; 93(2):216-222. PMC: 6944702. DOI: 10.1111/cge.13039. View